心房颤动合并颅内出血患者抗血栓药物治疗的有效性与安全性:系统综述与荟萃分析
该系统综述纳入20篇文章共50470例心房颤动合并非创伤性颅内出血患者,评估口服抗凝药和/或抗血小板药的有效性与安全性。口服抗凝药治疗与血栓栓塞事件(sRR 0.51)和全因死亡率(sRR 0.52)降低相关,未显著增加复发性颅内出血风险(sRR 1.44)。非维生素K拮抗剂口服抗凝药较华法林更有效减少血栓栓塞事件(sRR 0.65)且复发性颅内出血风险更低(sRR 0.52)。
要点
- 口服抗凝药与血栓栓塞事件降低相关(sRR 0.51,95%CI 0.30-0.86)
- 口服抗凝药与全因死亡率降低相关(sRR 0.52,95%CI 0.38-0.71)
- 非维生素K拮抗剂口服抗凝药较华法林复发性颅内出血风险更低(sRR 0.52)
核心结论
- 在合并非创伤性颅内出血的心房颤动存活者中,口服抗凝药治疗与血栓栓塞事件和全因死亡率降低相关,且未显著增加复发性颅内出血风险。
- 该结论主要基于观察性数据,需要进一步大型随机对照试验来证实或反驳这些发现。
研究设计与样本
- 系统综述与荟萃分析,检索CENTRAL、MEDLINE、EMBASE和CINAHL数据库。
- 纳入20篇文章共50470例参与者,包括2项随机对照试验(n=304)、8项观察性研究、8项队列研究和2项对观察性研究个体水平数据进行荟萃分析的研究。
- 纳入标准为成年心房颤动合并自发性颅内出血(脑内、硬膜下和蛛网膜下腔)并接受抗血栓治疗以预防卒中的患者。
主要发现
- 口服抗凝药治疗与血栓栓塞事件显著减少相关(汇总相对风险[sRR] 0.51,95%CI 0.30-0.86,异质性I²=2%,P=0.39,n=5项研究)。
- 口服抗凝药治疗与全因死亡率显著降低相关(sRR 0.52,95%CI 0.38-0.71,异质性I²=0,P=0.44,n=3项研究)。
- 口服抗凝药治疗与复发性颅内出血风险增加无关(sRR 1.44,95%CI 0.38-5.46,异质性I²=70%,P=0.02,n=5项研究)。
- 非维生素K拮抗剂口服抗凝药较华法林更有效减少血栓栓塞事件风险(sRR 0.65,95%CI 0.44-0.97,异质性I²=72%,P=0.03,n=3项研究),且与更低的复发性颅内出血风险相关(sRR 0.52,95%CI 0.40-0.67,异质性I²=0%,P=0.43,n=3项研究)。
局限性
- 该发现主要基于观察性数据。
- 需要进一步大型随机对照试验来证实或反驳这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with atrial fibrillation who survive an intracranial hemorrhage (ICrH), the decision to offer oral anticoagulation (OAC) is challenging and necessitates balancing risk of thromboembolic events with risk of recurrent ICrH. METHODS: This systematic review assesses the effectiveness and safety of OAC and/or antiplatelets in patients with atrial fibrillation with nontraumatic ICrH. Bibliographic databases CENTRAL, MEDLINE, EMBASE, and CINAHL were searched. Articles on adults with atrial fibrillation with spontaneous ICrH (intracerebral, subdural, and subarachnoid), receiving antithrombotic therapy for stroke prevention were eligible for inclusion. RESULTS: Twenty articles (50 470 participants) included 2 randomized controlled trials (n=304)' 8 observational studies, 8 cohort studies, and 2 studies that meta-analyzed individual-level data from observational studies. OAC therapy was associated with a significant reduction in thromboembolic events (summary relative risk [sRR], 0.51 [95% CI, 0.30-0.86], heterogeneity I2=2%; P=0.39, n=5 studies) and all-cause mortality (sRR, 0.52 [95% CI, 0.38-0.71], heterogeneity I2=0; P=0.44, n=3 studies). OAC therapy was not associated with an increased risk of recurrent ICrH (sRR, 1.44 [95% CI, 0.38-5.46], heterogeneity I2=70%, P=0.02, n=5 studies). Nonvitamin K antagonist OACs were more effective at reducing the risk of thromboembolic events (sRR, 0.65 [95% CI, 0.44-0.97], heterogeneity I2=72%, P=0.03, n=3 studies) and were associated with a lower risk of recurrent ICrH (sRR, 0.52 [95% CI, 0.40-0.67], heterogeneity I2=0%, P=0.43, n=3 studies) than warfarin. CONCLUSIONS: In nontraumatic ICrH survivors with atrial fibrillation, OAC therapy is associated with a reduced risk of thromboembolic events and all-cause mortality without significantly increasing risk of recurrent ICrH. This finding is primarily based on observational data, and further larger randomized controlled trials are needed to corroborate or refute these findings.
引用
- Ivany E, Ritchie LA, Lip GYH, et al. Effectiveness and Safety of Antithrombotic Medication in Patients With Atrial Fibrillation and Intracranial Hemorrhage: Systematic Review and Meta-Analysis. Stroke. 2022. PMID: 35862238. doi:10.1161/STROKEAHA.122.038752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。